Skip navigation
  • 中文
  • English

DSpace CRIS

  • DSpace logo
  • Home
  • Organizations
  • Researchers
  • Research Outputs
  • Explore by
    • Organizations
    • Researchers
    • Research Outputs
  • Academic & Publications
  • Sign in
  • 中文
  • English
  1. NTU Scholars
  2. 醫學院
  3. 醫學系
Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/566357
Title: Efficacy of clarithromycin-naproxen-oseltamivir combination therapy versus oseltamivir alone in hospitalized pediatric influenza patients
Authors: Lee C.-W.
Tai Y.-L.
LI-MIN HUANG 
Chi H.
Huang F.-Y.
Chiu N.-C.
Huang C.-Y.
Tu Y.-H.
Wang J.-Y.
Huang D.T.-N.
Keywords: Clarithromycin-naproxen-oseltamivir; Combination therapy; Influenza virus infection; Pediatric influenza
Issue Date: 2020
Publisher: Elsevier Ltd
Source: Journal of Microbiology, Immunology and Infection
Abstract: 
Purpose: This study aimed to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir therapy alone in hospitalized pediatric influenza patients. Methods: This prospective, single-blind study included children aged 1–18 years hospitalized with influenza, in MacKay Children's Hospital, Taiwan, between December 2017 and December 2019. The primary outcomes were the time to defervescence and decrease of the Pediatric Respiratory Severity Score (PRESS) during hospitalization. The secondary outcomes were serial changes in virus titers, measured using real-time polymerase chain reaction. Results: Fifty-four patients were enrolled (28 in the control group and 26 in the combination group) in total. There were no differences in the patients’ baseline characteristics between the groups. The time to defervescence was significantly shorter in the combination group than the oseltamivir group (13.2 h vs. 32.1 h, p = 0.002). The decrease in the virus titer from days 1–3 (log Δ13) was more pronounced in the combination group than the oseltamivir group. (39% vs. 19%, p = 0.001). There were no differences in adverse effects such as vomiting, diarrhea, and abdominal pain during the study or within 30 days after antiviral therapy. Conclusion: The clarithromycin-naproxen-oseltamivir combination group experienced a more rapid defervescence and a more rapid decline of influenza virus titer than the group treated with oseltamivir alone. Further consideration should be given to whether the overall benefits of combination therapy in hospitalized pediatric influenza patients outweigh the risks. ? 2020
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091862192&doi=10.1016%2fj.jmii.2020.08.017&partnerID=40&md5=b1b0f2badb608946aa4f127c59d53748
https://scholars.lib.ntu.edu.tw/handle/123456789/566357
ISSN: 1684-1182
DOI: 10.1016/j.jmii.2020.08.017
SDG/Keyword: amoxicillin plus clavulanic acid; azithromycin; clarithromycin; naproxen; oseltamivir; paracetamol; antivirus agent; clarithromycin; naproxen; nonsteroid antiinflammatory agent; oseltamivir; abdominal pain; antiviral therapy; Article; child; chill; combination drug therapy; controlled study; coughing; diarrhea; dizziness; drug efficacy; drug safety; dyspnea; female; headache; hospital patient; hospitalization; human; influenza; Influenza virus; major clinical study; male; myalgia; outcome assessment; pediatric patient; preschool child; prospective study; randomized controlled trial; real time polymerase chain reaction; rhinorrhea; school child; single blind procedure; sore throat; sputum; stridor; Taiwan; thorax pain; treatment response; virus load; vomiting; adolescent; combination drug therapy; drug effect; hospital; infant; influenza; pathology; treatment outcome; virology; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Female; Hospitalization; Hospitals, Pediatric; Humans; Infant; Influenza, Human; Male; Naproxen; Oseltamivir; Prospective Studies; Single-Blind Method; Treatment Outcome; Viral Load
[SDGs]SDG3
Appears in Collections:醫學系

Show full item record

SCOPUSTM   
Citations

8
checked on Feb 20, 2023

WEB OF SCIENCETM
Citations

7
checked on Mar 5, 2023

Page view(s)

18
checked on Mar 19, 2023

Google ScholarTM

Check

Altmetric

Altmetric

Related Items in TAIR


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Sherpa Romeo網站查詢,以確認出版單位之版權政策。
    Please use Sherpa Romeo to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)
Build with DSpace-CRIS - Extension maintained and optimized by Logo 4SCIENCE Feedback